Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease
- 31 March 2001
- journal article
- clinical trial
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 107 (3), 531-534
- https://doi.org/10.1067/mai.2001.113081
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- The role of lymphocytes in allergic diseaseJournal of Allergy and Clinical Immunology, 2000
- The environmental predictors of allergic diseaseJournal of Allergy and Clinical Immunology, 2000
- Randomised trial of intradermal Mycobacterium vaccae or intradermal hepatitis B immunisation in children with HIV infectionVaccine, 1999
- Effect of pre-immunization by killedMycobacterium bovisandvaccaeon immunoglobulin E response in ovalbumin-sensitized newborn micePediatric Allergy and Immunology, 1999
- Long-term Trends in TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAACThe Lancet, 1998
- Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccaeImmunology, 1998
- THE ORIGIN AND ERRATIC GLOBAL SPREAD OF TUBERCULOSIS: How the Past Explains the Present and Is the Key to the FutureClinics in Chest Medicine, 1997
- Asthma--An Epidemic in the Absence of Infection?Science, 1997
- The Inverse Association Between Tuberculin Responses and Atopic DisorderScience, 1997